Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ani Pharmaceuticals (ANIP) Gross Profit (2016 - 2025)

Historic Gross Profit for Ani Pharmaceuticals (ANIP) over the last 14 years, with Q3 2025 value amounting to $134.4 million.

  • Ani Pharmaceuticals' Gross Profit rose 5766.92% to $134.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $505.6 million, marking a year-over-year increase of 5222.82%. This contributed to the annual value of $364.2 million for FY2024, which is 1928.02% up from last year.
  • Ani Pharmaceuticals' Gross Profit amounted to $134.4 million in Q3 2025, which was up 5766.92% from $136.8 million recorded in Q2 2025.
  • Over the past 5 years, Ani Pharmaceuticals' Gross Profit peaked at $136.8 million during Q2 2025, and registered a low of -$8.8 million during Q1 2021.
  • Moreover, its 5-year median value for Gross Profit was $74.3 million (2023), whereas its average is $69.2 million.
  • Its Gross Profit has fluctuated over the past 5 years, first crashed by 13140.87% in 2021, then surged by 44383.61% in 2022.
  • Ani Pharmaceuticals' Gross Profit (Quarter) stood at $27.0 million in 2021, then soared by 114.22% to $57.9 million in 2022, then surged by 35.11% to $78.2 million in 2023, then surged by 40.98% to $110.3 million in 2024, then grew by 21.88% to $134.4 million in 2025.
  • Its Gross Profit was $134.4 million in Q3 2025, compared to $136.8 million in Q2 2025 and $124.1 million in Q1 2025.